Malaria Treatment and Medication Management in Patients with Roux-en-Y Gastric Bypass

Introduction to Medication Absorption Issues

• The bypassing of the proximal small intestine (duodenum) affects medication absorption in patients with Roux-en-Y gastric bypass, leading to unpredictable medication absorption and potential therapeutic failure due to reduced gastric capacity and altered gastric emptying 1, 2, 3
• Patients with Roux-en-Y gastric bypass may experience reduced gastric capacity and altered gastric emptying, resulting in potential therapeutic failure 2, 3

Alternative Antimalarial Medications

• The American Society of Clinical Microbiology recommends atovaquone-proguanil as a second-line option for patients with Roux-en-Y gastric bypass who require malaria treatment 4
• Quinine with doxycycline or clindamycin may be considered for patients with Roux-en-Y gastric bypass who require malaria treatment, as suggested by the Clinical Microbiology and Infection guidelines 4

Modified Dosing Strategies for Artemether-Lumefantrine

• The Swiss guidelines recommend extending the standard 3-day artemether-lumefantrine regimen to 5 days for patients with Roux-en-Y gastric bypass 4
• Administration of artemether-lumefantrine with high-fat supplements or meals is essential for patients with Roux-en-Y gastric bypass 4

General Medication Management

• Immediate-release (IR) formulations are preferred over extended-release (ER) formulations, and non-oral routes of administration (transdermal, injectable) should be considered when available, according to the American College of Clinical Pharmacy 2
• Liquid formulations without non-absorbable sugars should be used to avoid dumping syndrome, and opening capsules (if allowed) can improve absorption, as suggested by the European Society of Cardiology 5
• Therapeutic drug monitoring should be implemented when available, and patients should be monitored for signs of therapeutic failure or toxicity, with potential dose increases for medications showing decreased absorption, as advised by the American College of Clinical Pharmacy 2 and the American Gastroenterological Association 2

Outcomes and Complications of Roux-en-Y Gastric Bypass

• The procedure results in 25-30% loss of initial weight and achieves 50-65% loss of excess weight, with potential complications including anastomotic leaks, peritonitis, and pulmonary embolism, and a perioperative mortality rate of approximately 1% for open procedures 6, 7
• The following table summarizes the outcomes of Roux-en-Y reconstruction:

7, 8

• IV iron is the preferred treatment for iron deficiency anemia after RYGB, and regular medication reviews are essential due to changing absorption patterns over time, as recommended by the American Gastroenterological Association 2 and the European Society of Cardiology 5